Literature DB >> 3790385

Crescentic glomerulonephritis: a possible complication of streptokinase treatment for myocardial infarction.

N Murray, J Lyons, M Chappell.   

Abstract

Twenty days after a streptokinase infusion given for myocardial infarction, a patient developed a group G streptococcal throat infection. Thirteen days later he presented with a serum sickness type illness and progressive renal failure. Renal biopsy showed crescentic glomerulonephritis.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3790385      PMCID： PMC1236899          DOI： 10.1136/hrt.56.5.483

Source DB:  PubMed          Journal:  Br Heart J        ISSN： 0007-0769


  9 in total

1.  Antigen quantitation in experimental immune complex glomerulonephritis. I. Acute serum sickness.

Authors:  C B Wilson; F J Dixon
Journal:  J Immunol       Date:  1970-08       Impact factor: 5.422

2.  Tissue plasminogen activator (t-PA). Will it fulfill its promise?

Authors:  S Sherry
Journal:  N Engl J Med       Date:  1985-10-17       Impact factor: 91.245

3.  Acute renal failure following repeated streptokinase therapy for pulmonary embolism.

Authors:  R A Pick; B C Joswig; A K Cheung; I M Cohen
Journal:  West J Med       Date:  1983-06

4.  Serum sickness following streptokinase therapy.

Authors:  W G Totty; T Romano; G M Benian; L A Gilula; L A Sherman
Journal:  AJR Am J Roentgenol       Date:  1982-01       Impact factor: 3.959

5.  Acute renal failure, hypertension and skin necrosis in a patient with streptokinase therapy.

Authors:  R J Glassock; E Ritz; J Bommer; K Andrassy; R Waldherr
Journal:  Am J Nephrol       Date:  1984       Impact factor: 3.754

6.  Streptokinase-induced anaphylactic reaction.

Authors:  T G Baumgartner; R G Davis
Journal:  Clin Pharm       Date:  1982 Sep-Oct

7.  Current concepts: guidelines for the use of thrombolytic agents.

Authors:  W R Bell; A G Meek
Journal:  N Engl J Med       Date:  1979-12-06       Impact factor: 91.245

8.  [Acute renal failure due to diffuse cholesterol crystal embolisation during streptokinase treatment (author's transl)].

Authors:  F W Rieben; R Waldherr; P Oster; G Schettler
Journal:  Dtsch Med Wochenschr       Date:  1979-10-12       Impact factor: 0.628

9.  A comparative histologic and immunologic study in rabbits of induced hypersensitivity of the serum sickness type.

Authors:  F G GERMUTH
Journal:  J Exp Med       Date:  1953-02-01       Impact factor: 14.307
  9 in total
  8 in total

1.  Serum sickness and purpura following intravenous streptokinase.

Authors:  G J Clesham; H J Terry; S Jalihal; P J Toghill
Journal:  J R Soc Med       Date:  1992-10       Impact factor: 5.344

2.  Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

Authors:  J D Gemmill; M Sandler; W S Hillis; J Tillman; R Wakeel
Journal:  Br Heart J       Date:  1988-10

Review 3.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

4.  Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

Authors:  C Bucknall; C Darley; J Flax; R Vincent; D Chamberlain
Journal:  Br Heart J       Date:  1988-01

5.  Acute renal failure following intravenous streptokinase infusion for acute myocardial infarction.

Authors:  Y Birnbaum; B Strasberg; E Rechavia; Y Neuman; B Stahl
Journal:  West J Med       Date:  1993-04

Review 6.  Comparative tolerability profiles of thrombolytic agents. A review.

Authors:  K S Woo; H D White
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

7.  Henoch-Schoenlein purpura due to streptokinase.

Authors:  A P Zilliox; D T Domoto; P S Hutcheson; C C Tsai; R G Slavin
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

Review 8.  Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.

Authors:  P E Battershill; P Benfield; K L Goa
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.